B-Cell Non-Hodgkin Lymphoma CRISPR Cell Models for Drug Discovery

According to the World Health Organization (WHO), non-Hodgkin lymphoma (NHL) accounts for approximately 2.8% of all cancer cases globally, with an estimated 544,000 new cases and 260,000 deaths annually. B-cell NHL represents about 85-90% of all NHL cases. The National Cancer Institute (NCI) reports a 5-year relative survival rate of 73% for all NHL stages combined, but this varies significantly by subtype: diffuse large B-cell lymphoma (DLBCL) has a 5-year survival of 64%, while follicular lymphoma (FL) has 89%. Key risk factors include immunosuppression (HIV, organ transplant), autoimmune diseases (e.g., Sjogren syndrome), and infections (e.g., Helicobacter pylori, Epstein-Barr virus).

B-cell NHL is an ideal model for mechanistic studies due to its well-characterized molecular subtypes (e.g., germinal center B-cell (GCB) and activated B-cell (ABC) DLBCL), availability of large public datasets (TCGA, COSMIC), and numerous established cell lines. Open questions include the role of tumor microenvironment interactions, mechanisms of resistance to targeted therapies (e.g., ibrutinib, venetoclax), and the functional impact of recurrent mutations in epigenetic regulators (e.g., EZH2, KMT2D).

The pathogenesis of B-cell NHL involves several key pathways:

1. B-cell receptor (BCR) signaling: Chronic active BCR signaling drives survival and proliferation in ABC-DLBCL.

• • Steps: Antigen-independent BCR clustering -> SYK activation -> BTK phosphorylation -> PLCgamma2 activation -> NF-kB and MAPK pathways.

2. NF-kB pathway: Constitutive activation is a hallmark of ABC-DLBCL.

• • Steps: MYD88 L265P mutation -> IRAK1/4 activation -> TRAF6 ubiquitination -> IKK complex -> IkB degradation -> NF-kB nuclear translocation.

3. PI3K/AKT/mTOR pathway: Frequently activated via PTEN loss or PIK3CA mutations.

• • Steps: PI3K activation -> PIP3 generation -> AKT phosphorylation -> mTORC1 activation -> protein synthesis and cell growth.

4. Apoptosis regulation: BCL2 overexpression (via t(14;18) translocation) blocks apoptosis in FL and some DLBCL.

Data from TCGA and COSMIC databases.

Key deregulated networks in B-cell NHL:

• • BCR signaling network:
• • BTK, SYK, PLCgamma2, PKCbeta, CARD11, BCL10, MALT1
• • NF-kB network:
• • MYD88, IRAK1, IRAK4, TRAF6, IKKalpha, IKKbeta, IKKgamma, RELA, RELB
• • PI3K/AKT/mTOR network:
• • PIK3CA, PIK3CD, PTEN, AKT1, AKT2, TSC1, TSC2, RHEB, mTOR, S6K1, 4E-BP1
• • Epigenetic regulation network:
• • EZH2, KMT2D, CREBBP, EP300, MEF2B, TET2, DNMT3A
• • Apoptosis network:
• • BCL2, BCL2L1, BAX, BAK, BIM, BAD, MCL1, BCL2L11

Commonly used B-cell NHL cell lines:

Organoid models: Patient-derived organoids (PDOs) from B-cell NHL are emerging, offering 3D architecture and tumor microenvironment interactions. They retain genetic heterogeneity and drug response profiles, but are more complex to establish and maintain.

Animal models for B-cell NHL:

• • Patient-derived xenograft (PDX) models:
• • Subcutaneous or intravenous injection of patient tumor cells into immunodeficient mice (e.g., NSG, NOG).
• • Examples: PDX models of ABC-DLBCL, FL, mantle cell lymphoma.
• • Genetically engineered mouse models (GEMMs):
• • VavP-BCL2: BCL2 overexpression in B cells, develops FL-like disease.
• • Eµ-MYC: MYC overexpression in B cells, develops Burkitt-like lymphoma.
• • CD19-Cre;KMT2D flox/flox: KMT2D deletion, develops DLBCL.
• • Induced models:
• • AID-driven: Activation-induced cytidine deaminase overexpression induces mutations.
• • Chemical carcinogen: ENU treatment in mice.

CRISPR/Cas9 gene editing enables the creation of isogenic cell lines that differ only in a specific genetic alteration, providing a clean system to study gene function. Examples include:

• • TP53 knockout models: TP53-/- isogenic lines in OCI-Ly1 or SU-DHL-4 to study loss of tumor suppression.
• • MYD88 L265P knock-in: Introduction of the L265P mutation into MYD88 wild-type lines (e.g., OCI-Ly1) to model constitutive NF-kB activation.
• • EZH2 Y641N knock-in: Generation of EZH2 mutant lines to study epigenetic changes.
• • BCL2 overexpression: CRISPR-mediated insertion of BCL2 expression cassette to model t(14;18).
• • CD79B knockout: Disruption of CD79B to study BCR signaling dependence.

Commercially available, sequence-verified, and mycoplasma-free gene-edited cell models accelerate research by reducing the time and cost of in-house generation. These models are validated by Sanger sequencing, western blot, and functional assays.

Gene-edited cell lines are essential for functional validation of candidate driver genes identified by sequencing studies. Examples:

• • Validation of KMT2D as a tumor suppressor: KMT2D knockout in GCB-DLBCL lines leads to increased proliferation and altered H3K4 methylation.
• • EZH2 gain-of-function: EZH2 Y641N knock-in increases H3K27me3 levels and promotes cell growth.
• • TP53 loss: TP53 knockout in DLBCL lines confers resistance to DNA-damaging agents and enhances genomic instability.
• • MYD88 L265P: Knock-in of MYD88 L265P in wild-type lines activates NF-kB and increases cell survival.

Isogenic pairs (wild-type vs. mutant) are powerful tools for drug screening and resistance studies:

• • BTK inhibitor resistance: Generation of BTK C481S knock-in in TMD8 cells to model ibrutinib resistance.
• • BCL2 inhibitor resistance: BCL2 G101V knock-in in SU-DHL-4 cells to study venetoclax resistance.
• • EZH2 inhibitor sensitivity: EZH2 Y641N knock-in lines show increased sensitivity to tazemetostat.
• • Combination screening: Isogenic pairs allow identification of synthetic lethal partners (e.g., EZH2 mutant + BCL2 inhibitor).

CRISPR-based screens in gene-edited cell lines enable biomarker discovery:

• • Synthetic lethality screens: Genome-wide CRISPR screens in MYD88 L265P knock-in lines identify IRAK1/4 as synthetic lethal targets.
• • Resistance mechanisms: CRISPR screens in TP53 knockout lines identify genes whose loss confers resistance to chemotherapy.
• • Immune evasion: Knockout of MHC class I components in DLBCL lines to study immune checkpoint inhibitor response.